Supriya Lifescience Limited has announced an earnings call scheduled for November 13, 2025, at 11:00 AM IST to discuss its unaudited financial results for the quarter and half-year ending September 30, 2025. This call will provide insights into the company's operational and financial performance, a critical update for stakeholders. The invitation also notes that a presentation will be shared with stock exchanges, ensuring that investors have access to comprehensive information.

The earnings call will feature key management representatives, including Dr. Satish Wagh, Executive Chairman, and Dr. Saloni Wagh, Managing Director, alongside Mr. Krishna Raghunathan, Chief Financial Officer. Participants can register via a provided link and access the call through various international dialing numbers, reflecting the company’s commitment to transparency and investor engagement.

Supriya Lifescience, listed on both the National Stock Exchange (NSE: SUPRIYA) and BSE (Scrip Code: 543434), continues to operate from its corporate office in Mumbai and its manufacturing facility located in Ratnagiri, Maharashtra. As a government-recognized export house, the company is poised to share its strategies and financial outlook, highlighting its role in the global healthcare sector.